Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA as defined by the 1987 or 2010 revised American College of Rheumatology (ACR) criteria~* Early RA (less than 1 year)~* Use a reliable method of contraception for women of childbearing potential~* Able and willing to give written informed consent and participate in the study~Exclusion Criteria:~* Previous treatment with DMARDs~* Previous treatment with oral corticosteroids at a dosage of more than 10 milligrams (mg) prednisone within 4 weeks before baseline~* Previous treatment with oral corticosteroids at a dosage equal to or less than 10 mg prednisone within 2 weeks before baseline~* Previous treatment with oral corticosteroids for more than 4 weeks~* Previous treatment with Intra Articular corticosteroids within 4 weeks before baseline~* Previous treatment with an investigational drug for the treatment or prevention of RA~* Contraindications for corticosteroids~* Contraindications for DMARDs~* Psoriatic Arthritis~* Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases or immune deficiency which in the opinion of the investigator places the patient at an unacceptable risk for participation in the study~* Pregnancy, breastfeeding or no use of a reliable method of contraception~* Alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CoBRA classic high risk group (Type: OTHER): * Methotrexate 15mg tablet by mouth, weekly for entire trial~* Sulfasalazine 2g tablet by mouth, daily for 40 weeks~* Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32
- CoBRA slim high risk group (Type: OTHER): * Methotrexate 15mg tablet by mouth, weekly for entire trial~* Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32
- CoBRA avant-garde high risk group (Type: OTHER): * Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)~* Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)~* Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32
- CoBRA slim low risk group (Type: OTHER): * Methotrexate 15mg tablet by mouth, weekly for entire trial~* Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32
- Tight Step Up low risk group (Type: OTHER): * Methotrexate 15mg tablet by mouth, weekly for entire trial~* No oral steroids allowed during the first year of the trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete